Kompleksnoe lechenie erektil'noy disfunktsii u muzhchin s ozhireniem


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Obesity is one of the most important public health problems due to their common association with many chronic diseases including metabolic syndrome, type 2 diabetes, cardiovascular disease, dyslipidemia. Moreover, obesity is associated with a high prevalence of erectile dysfunction (ED); however, the pathophysiological link between these states are still poorly understood. A major role in the treatment of erectile dysfunction in obese men, along with drugs aimed at the normalization of erection should take therapy that promotes weight loss. Treatment of ED and obesity should be carried out simultaneously, as the simultaneous existence of these two pathologies support depression, which significantly worsens the prognosis of treatment. Therefore, in men with erectile dysfunction, obesity and requires the use of combined treatment aimed at reducing body weight, and sexual dysfunction. In this study, the findings suggest that the positive effect of weight loss, and as a result reduce the impact of the phenomenon of lipotoxicity on androgen status in men with obesity. It was shown that the weight loss program is not sufficiently effective, and that in men with ED, obesity and drug treatment should be carried out.

Full Text

Restricted Access

About the authors

A. S Ametov

M. V Stel'makh

Email: mariastel@mail.ru

References

  1. James P.T., Leach R., Kalamara E., Shayeghi M. The worldwide obesity epidemic. Obes. Res. 2001; 9(Suppl. 4): 228S-3S.
  2. Spence-Jones G. Overview of obesity. Crit. Care Nurs. 2003; 26: 83-88.
  3. Lue T., Basson R., Rosen R., et al. Sexual medicine. Sexual dysfunction in men and women. Second international consultation on sexual dysfunction. Paris: Health Publication; 2004.
  4. Rosen R.C., Wing R.R., Schneider S., et al. Erectile dysfunction in type 2 diabetic men: relationship to exercise fitness and cardiovascular risk factors in the Look AHEAD trial. J. Sex. Med. 2009; 6: 1414-22.
  5. Demir T., Demir O., Kefi A., et al. Prevalence of erectile dysfunction in patients with metabolic syndrome. Int. J. Urol. 2006; 13: 385-88.
  6. Bal K., Oder M., Sahin A.S., et al. Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: metabolic backgrounds of erectile dysfunction. Urology. 2007; 69: 356-60.
  7. Esposito K., Giugliano F., Martedi E., et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care. 2005; 28: 1201-203.
  8. Heidler S., Temml C., Broessner C., et al. Is the metabolic syndrome an independent risk factor for erectile dysfunction? J. Urol. 2007; 177: 651-54.
  9. Grover S.A., Lowensteyn I., Kaouache M., et al. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch. Intern. Med. 2006; 166: 213-19.
  10. Мазо Е.Б., Гамидов С.И., Иремашвили В.В. Эректильная дисфункция. М., 2008. C. 5-14.
  11. Esposito K., Giugliano F., Di Palo C., et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004; 291: 2978-84.
  12. Huang P.L. A comprehensive definition for metabolic syndrome. Dis. Model. Mech. методы лечения и профилактики данного расстройства. Таким образом, опыт отечественных и зарубежных исследователей по этиологии, патогенезу и терапии ЭД на фоне ожирения свидетельствует о значительном прогрессе в плане выявления 2009; 2: 231-37.
  13. Stehouwer C.D., Henry R.M., Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia. 2008; 51: 527-39.
  14. Creager M.A., Löscher T.F., Cosentino F., Beckman J.A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation. 2003; 108: 1527-32.
  15. Yassin A.A., Saad F., Gooren L.J. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia. 2008; 40: 259-64.
  16. Kupelian V., Hayes F.J., Link C.L., et al. Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. J. Clin. Endocrinol. Metab. 2008; 93: 3403-10.
  17. Corona G., Mannucci E., Ricca V., et al. The agerelated decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int. J. Androl. 2009; 32: 720-28.
  18. Goncharov N.P., Katsya G.V., Chagina N.A., Gooren L.J. Three definitions of metabolic syndrome applied to a sample of young obese men and their relation with plasma testosterone. Aging Male. 2008; 11: 118-22.
  19. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J. Clin. Oncol. 2006; 24: 3979-83.
  20. Lee M.J., Fried S.K. Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion. Am. J. Physiol. Endocrinol. Metab. 2009; 296: E1230-38.
  21. McConway M.G., Johnson D., Kelly A., et al. Differences in circulating concentrations of total, free and bound leptin relate to gender and body composition in adult humans. Ann. Clin. Biochem. 2000; 37: 717-23.
  22. Kapoor D., Clarke S., Stanworth R., et al. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol. 2007; 156: 595-602.
  23. Isidori A.M., Caprio M., Strollo F., et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J. Clin. Endocrinol. Metab. 1999; 84: 3673-80.
  24. Luukkaa V., Pesonen U., Huhtaniemi I., et al. Inverse correlation between serum testosterone and leptin in men. J. Clin. Endocrinol. Metab. 1998; 83: 3243-6.
  25. Niskanen L., Laaksonen D.E., Punnonen K., et al. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes. Metab. 2004; 6: 208-15.
  26. Бутрова С.А., Берковская М.А., Комшилова К.А. Опыт применения препарата Редуксин (сибутрамин) у больных с метаболическим синдромом. М., http://medi.ru/doc/a200303.htm
  27. Van Gaal L.F., Wauters M.A., Peiffer F.W., De Leeuw I.H. Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/ visceral fat reduction? Int. J. Obes. Relat. Metab. Disord. 1998; 22: 38-40.
  28. Кондрашкина О.В. Дисс.. канд. мед. наук. Влияние сибутрамина на половую функцию у мужчин с ожирением. М., 2007. С. 58-9.
  29. Щеплев П.А., Гвасалия Б.Р., Гарин Н.Н., Данилов И.А. Опыт применения фитотерапии в лечении эректильной дисфункции. Профессиональная ассоциация андрологов России. Андрология и генитальная хирургия. 2007; 3.
  30. http://railis.ru/pochemu-rajlis/rezultaty-issle-dovanij//
  31. Gorbachinsky I., Akpinar H., Assimos D.G. Metabolic Syndrome and Urologic Diseases. Rev Urol. 2010l; 12(4): e157-80.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies